Nephros Stock News

Nephros Inc (NEPH) shares closed today at 0.4% above its 52 week low of $5.58, giving the company a market cap of $58M. The stock is currently down 2.5% year-to-date, down 26.3% over the past 12 months, and up 432.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 6.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 18.7% The company's stock price performance over the past 12 months lags the peer average by -1452.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nephros Inc (NEPH) shares closed today at 1.7% above its 52 week low of $5.58, giving the company a market cap of $58M. The stock is currently down 3.8% year-to-date, down 27.4% over the past 12 months, and up 425.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 88.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 56.0% The company's stock price performance over the past 12 months lags the peer average by -1761.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nephros Inc (NEPH) shares closed today at 0.8% above its 52 week low of $5.65, giving the company a market cap of $58M. The stock is currently down 3.5% year-to-date, down 29.4% over the past 12 months, and up 427.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 17.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 96.8% The company's stock price performance over the past 12 months lags the peer average by -867.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cowen Prime Advisors LLC raised its position in shares of Nephros, Inc. (NASDAQ:NEPH) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 660,150 shares of the companys stock after buying an additional 33,700 shares during the quarter. Nephros comprises approximately 2.2% []

LeMaitre Vascular (NASDAQ:LMAT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Profitability This table compares LeMaitre Vascular and Nephros net margins, return on equity and return on []

Arch Therapeutics (OTCMKTS:ARTH) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Institutional & Insider Ownership 0.0% of Arch Therapeutics shares are held by institutional investors. Comparatively, 58.0% []

SOUTH ORANGE, NJ, Nov. 23, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solu

Nephros (NASDAQ:NEPH) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership. Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Nephros and Arch Therapeutics, []

Nephros (NASDAQ:NEPH) and Sigyn Therapeutics (NASDAQ:SIGY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Analyst Recommendations This is a breakdown of current ratings for Nephros and Sigyn Therapeutics, as provided []

South Orange, New Jersey--(Newsfile Corp. - November 8, 2021) - Nephros, Inc. (NASDAQ: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to hea

Nephros, Inc. (NEPH) CEO Andy Astor on Q3 2021 Results - Earnings Call Transcript

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0.00% and 0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SOUTH ORANGE, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire –   Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to

Anticipates Net Revenue of $2.6 Million, a 24% Year-Over-Year Increase

SOUTH ORANGE, NJ, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection sol